According to statistics, one person in China suffers from cancer every five minutes, and the demand for high-precision cancer genetic testing is increasing. Action Gene, a domestic genetic testing industry, launched "Large-scale Cancer Genetic Testing", which uses cutting-edge genetic testing technology and professional biomedical and bioinformatics analysis to find drug choices for patients with advanced cancer. This test won the National Innovation Award of 20 18, and is currently applying for IVD FDA in-vitro diagnostic equipment certification.
"Cancer Genetic Testing" Award-winning Precision Medical Leap Forward
Chen Huajian, CEO of the award-winning genetic testing company, said that he won this year's national innovation award "Precision Medicine Award". In addition to thanking the jury for their affirmation of product technology and innovation, it is also because of the cooperative efforts of the team that we have the opportunity to win the prize. In the future, we will continue to promote precision medicine and let the public know more about genetic testing.
Chen Huajian explained that they have more than 65,438+05 years of experience in pharmaceutical industry, biomarkers and medical information. In addition to setting up a laboratory certified by the American Pathology Association (CAP) in Taiwan Province Province and providing complete genetic testing technical assistance in major hospitals in China, they have also completed related projects in Singapore, Japan, Hong Kong and mainland China, and this award has greatly enhanced their professional position in the field of precision medicine in Asia.
/kloc-make a treatment strategy in 0/4 days, and 80% of friends with advanced cancer will benefit.
"Extensive detection of tumor genes" is to use NGS to extensively detect 440 tumor drug-related genes in tumor tissue samples at one time, and provide drug suggestions such as targeted therapy, immunotherapy, hormone therapy and chemotherapy within 14 days to help clinicians formulate accurate treatment strategies. At present, more than 80% patients with advanced cancer have been successfully assisted to find drug choices.
In addition, more drug selection suggestions can be provided for cancer patients, including those who are newly diagnosed with advanced cancer, recurrent and metastatic cancer, advanced cancer that needs differential diagnosis, cancer patients who find other treatment strategies ineffective, or patients with rare and unknown primary cancer.
The success of biomarker research will certainly contribute to the improvement of immunotherapy.
Chen Huajian, CEO, said that although immunotherapy is a popular treatment choice for cancer at present, and it has the opportunity to achieve a cure effect, the effective rate of immunotherapy for tumors is only about 25%, and it is easy to produce side effects due to autoimmune factors, and the treatment cost is expensive. Therefore, selecting cancer patients with high response rate to immunotherapy through effective biomarkers is also a precise medical direction to effectively improve the success rate in the future.
Chen Huajian said that in May this year, they were favored by American cancer research institutions because of their calculation mechanism for accurately predicting immune efficacy, and were selected to participate in the research project of developing the latest international evaluation standard of immunotherapy-Tumor Mutation Burden (TMB), becoming the only Asian genetic testing company selected outside the United States. At present, in the research results published in the first phase, it leads other testing companies with excellent performance closer to the standard value and becomes a new generation of Asian light.
In addition to continuing to cooperate with hospitals at home and abroad to help doctors make more accurate medical strategies through genetic testing, CEO Chen Huajian said that they have also accumulated a huge amount of genetic testing data, which can be used as a reference for international pharmaceutical companies to develop drugs. In addition, we are also actively cooperating with technology companies to develop gene detection chips, which are developing into IVD in vitro diagnostic equipment, and are currently applying for FDA certification.
Join us and pay attention to your health every day! Line @ ID: @ Subscribe to health ALOHO audio-visual channel to read health knowledge more easily: /beauty/article/40470 Keywords: CEO Chen Huajian, extensive cancer genetic testing, national innovation award, CAP certified laboratory, next-generation sequencing, providing drug choices for patients with advanced cancer.